HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

3- (4- methylpiperazin- 1- yl)- 5- (3- nitrobenzylamino)- 7- (trifluoromethyl)quinoline

a c-Met kinase inhibitor with antineoplastic activity; structure in first source

Also Known As:

SOMG-833

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperazines: 26
    - 3-(4-methylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7-(trifluoromethyl)quinoline: 1
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - Aminoquinolines: 29
        3-(4-methylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7-(trifluoromethyl)quinoline: 1

Experts

1.	Ai, Jing: 1 article (07/2014)
2.	Chen, Yi: 1 article (07/2014)
3.	Ding, Jian: 1 article (07/2014)
4.	Geng, Mei-yu: 1 article (07/2014)
5.	He, Chang-xi: 1 article (07/2014)
6.	Huang, Min: 1 article (07/2014)
7.	Ji, Yin-chun: 1 article (07/2014)
8.	Wang, Lu: 1 article (07/2014)
9.	Yang, Jing-yu: 1 article (07/2014)
10.	Zhang, Ao: 1 article (07/2014)

Related Diseases

1.

Neoplasms (Cancer)

07/01/2014 - "In a panel of 24 human cancer or genetically engineered model cell lines, SOMG-833 potently inhibited c-MET-driven cell proliferation, whereas cancer cells lacking c-MET activation were markedly less sensitive (at least 15-fold) to the treatment. "
07/01/2014 - "Collectively, our results suggested SOMG-833 as a promising candidate for highly selective c-MET inhibition and a powerful tool to investigate the sole role of MET kinase in cancer. "

Related Drugs and Biologics

1.	Phosphotransferases (Kinase)